Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Chimeric chains for receptor-associated signal transduction pathways |
| Inventors: | Capon, Daniel J.; Hillsborough, CA, USA Weiss, Arthur; Mill Valley, CA, USA Irving, Brian A.; San Francisco, CA, USA Roberts, Margo R.; San Francisco, CA, USA Zsebo, Krisztina; Woodside, CA, USA |
| Summary: | Described herein are T cells that express proteins which bind to virus and tumor antigens and which can kill cells presenting the antigens, via the activity of a cytoplasmic signal transducing domain. The invention relates to chimeric proteins and the DNA encoding such proteins, wherein the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner. Further disclosed is the transmembrane domain and a cytoplasmic domain, capable of activating a signaling pathway, although the extracellular domain and cytoplasmic domain are not naturally found together. Also provided are the means by which the ligand binds to the extracellular domain resulting in transduction of a signal and activation of a signaling pathway in the cell, such that the cell may be induced to carry out various functions relating to the signaling pathway. Further included are multiple extracellular domains which may be employed as receptors, wherein such domains may be naturally occurring or synthetic. Therapeutic applications of such chimeric DNA include the treatment of HIV, other viral infections and malignancies via the modification of lymphocytes as well as of hematopoietic precursor stem cells. |
| Abstract: | Chimeric proteins and DNA encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US6319494 |
| Application Number: | US1995000479737 |
| Date Filed: | 07/06/1995 |
| Date Published: | 20/11/2001 |
| Assignee: | Cell Genesys, Inc., Foster City, CA, USA |